News Archive

2 Nov. 2010

Development of Biomay´s BM32 vaccine for grass pollen allergy progressing according to plan

Biomay announces that the development programme of BM32 – a new vaccine for immunotherapy of grass pollen allergy – is progressing well and according to plan.[more]

20 Jan. 2010

New Aliquot Sizes and Prices of Research-grade Recombinant Allergens

Biomay wishes to inform its customers about a few changes in the distribution of its research-grade recombinant allergens.[more]

27 Jul. 2009

Biomay and RBPS-Technologies Sign Agreement for GMP Minicircle DNA

Biomay and RBPS-Technologies announce their manufacturing cooperation for production of GMP-grade minicircle DNA.[more]

22 Jul. 2009

Biomay Partner Ferreira Lectured at Austrian Embassy in Washington

Dr. Fatima Ferreira, Austrian Scientist of Year 2008 and Biomay´s scientific partner, gave a lecture at the Embassy of Austria in Washington, DC, on June 29, 2009.[more]

21 Mar. 2009

Austrian Allergy Cluster is Going International

The launch of the “Christian Doppler Laboratory for the Development of Allergen Chips” at the Medical University of Vienna, led by Univ. Doz. Dr. Susanne Vrtala, is further strengthening the Austrian Allergy Cluster.[more]

11 Feb. 2009

Biomay Offers GMP Allergens off the Shelf

Biomay announced to offer GMP-grade allergens as active pharmaceutical ingredients off the shelf.[more]

8 Jan. 2009

Fatima Ferreira Elected "Scientist of the Year 2008"

The allergologist Fatima Ferreira, director of the Christian Doppler Laboratory of Allergy Diagnosis and Research at the University of Salzburg, has been elected "Scientist of the Year 2008".[more]

5 Jan. 2009

Biomay Enters GMP Contract Manufacturing Business

Biomay has started to offer GMP contract manufacturing services for microbial-derived recombinant proteins and plasmid DNA.[more]

1 Oct. 2008

Biomay Starts GMP Operations

Biomay has started GMP operations for manufacturing recombinant biopharmaceuticals.[more]

1 Oct. 2008

Biomay Joins EU Project “Food Allergy Specific Immuno - Therapy” / FAST

Biomay participates in the EU project “FAST” (Food Allergy Specific Immunotherapy), the kickoff meeting of which was recently held in Madrid.[more]

Displaying 21 to 30 of 38

Biomay AG completes capital increase in the amount of €2.8 million from existing investors

Biomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding shares to 20 million. The fresh capital will be employed to complete the ongoing phase IIb studies with lead product BM32, an innovative grass pollen vaccine and advance its pipeline products to full preclinical development. Rainer Henning, CEO of Biomay commented: „We are very grateful to our shareholders, which again have demonstrated their long term commitment to the company and their faith in the successful development of our breakthrough products“. About Biomay: Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens. Biomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding shares to 20 million. The fresh capital will be employed to complete the ongoing phase IIb studies with lead product BM32, an innovative grass pollen vaccine and advance its pipeline products to full preclinical development. Rainer Henning, CEO of Biomay commented: „We are very grateful to our shareholders, which again have demonstrated their long term commitment to the company and their faith in the successful development of our breakthrough products“. About Biomay: Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens. www.biomay.com